San Francisco, United States
Journey Colab is a biotech startup dedicated to developing FDA-approved, psychedelic therapies with a focus on synthetic mescaline. Founded in 2020 and headquartered in the United States, the company received a significant $15.71M investment in a Venture Round on 01 November 2021, with participation from Lionheart Ventures and Delphi VC.
Their mission is to revolutionize addiction care by leveraging the potential of neuroplasticity-promoting therapeutics, psychotherapy, and community support. The company's lead compound, synthetic Mescaline HCl, targets patients struggling with alcohol use disorder (AUD), aiming to provide durable remission for this chronic, relapsing condition. Journey Colab is committed to creating scientifically rigorous and clinically validated treatments while prioritizing equitable access to care.
Operating in the Health Care and Pharmaceutical industries, Journey Colab's innovative approach and dedication to addressing a critical societal issue make it an intriguing investment opportunity in the evolving landscape of biotech and mental health therapeutics. With a clear focus on scientific rigor, clinical validation, and stakeholder engagement, this startup has the potential to make a significant impact on the addiction treatment market while paving the way for further innovations in psychedelic therapy.
